Amylyx Pharmaceuticals (AMLX) Total Liabilities (2021 - 2026)

Amylyx Pharmaceuticals' Total Liabilities history runs 6 years deep, the most recent figure standing at $20.4 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 11.96% year-over-year to $20.4 million in Q1 2026; TTM through Mar 2026 was $20.4 million, a 11.96% increase from a year earlier, with the FY2025 full-year figure at $27.4 million, down 5.14% from the prior year.
• Total Liabilities declined to $20.4 million in Q1 2026 per AMLX's latest filing, from $27.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $93.0 million in Q1 2024 and bottomed at $18.3 million in Q1 2025.
• The 5-year median for Total Liabilities is $37.4 million (2022), against an average of $45.9 million.
• Across the five-year window, Total Liabilities surged 191.7% in 2022 and tumbled 80.37% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $50.8 million in 2022, then surged by 65.25% to $84.0 million in 2023, then sank by 65.64% to $28.9 million in 2024, then retreated by 5.14% to $27.4 million in 2025, then declined by 25.36% to $20.4 million in 2026.
• Per Business Quant, the three latest AMLX Total Liabilities figures stand at $20.4 million (Q1 2026), $27.4 million (Q4 2025), and $30.7 million (Q3 2025).